RxDoctor Payments Data

Michelle Tong

Gastroenterology · Torrington, CTNPI 1659798023

Payments from drug & device makers

$4,303in general payments, 2019–2025

Across 180 payments — averaging $23.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$417
  • Takeda Pharmaceuticals U.S.A., Inc.$371
  • Gilead$203
  • Bristol Myers Squibb$190
  • Pfizer$188
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$4,12296%
  • Education$1814%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,303 in reported general payments places this provider in the 50th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$86,218
Medicare patients
253
Services billed
2,759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin22$68,170
LinzessLinaclotide57$49,090
ZenpepLipase/Protease/Amylase14$43,819
Mesalamine17$10,759
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates102$6,207
SutabSod Sulf/Pot Chloride/Mag Sulf24$3,875
Pantoprazole Sodium234$3,462
Sucralfate29$2,480
CholestyramineCholestyramine (With Sugar)14$1,758
Omeprazole66$1,413
Ondansetron OdtOndansetron22$1,209
Famotidine71$1,189
Esomeprazole Magnesium22$1,156
Budesonide EcBudesonide11$933
Dicyclomine Hcl33$452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$172$68,17022 claims
AbbVieLinzess$1,252$49,09057 claims
Aimmune Therapeutics, Inc.Zenpep$64$43,81914 claims
Braintree Laboratories, Inc.Sutab$31$3,87524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Torrington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →